{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T16:12:04Z","timestamp":1794672724931,"version":"4.9.1"},"publisher-location":"New York, NY","reference-count":163,"publisher":"Springer US","isbn-type":[{"value":"9781071610152","type":"print"},{"value":"9781071610169","type":"electronic"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1007\/978-1-0716-1016-9_1","type":"book-chapter","created":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T05:19:23Z","timestamp":1618291163000},"page":"1-20","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Benefits of Complement Measurements for the Clinical Practice"],"prefix":"10.1007","author":[{"given":"Anne","family":"Grunenwald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubka T.","family":"Roumenina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,14]]},"reference":[{"key":"1_CR1","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3389\/fimmu.2015.00262","volume":"6","author":"NS Merle","year":"2015","unstructured":"Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT (2015) Complement system part I\u2014molecular mechanisms of activation and regulation. Front Immunol 6:262","journal-title":"Front Immunol"},{"key":"1_CR2","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.4049\/jimmunol.156.8.3051","volume":"156","author":"MA Naughton","year":"1996","unstructured":"Naughton MA et al (1996) Extrahepatic secreted complement C3 contributes to circulating C3 levels in humans. J Immunol 156:3051\u20133056","journal-title":"J Immunol"},{"key":"1_CR3","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1146\/annurev-immunol-030409-101250","volume":"28","author":"C Kemper","year":"2010","unstructured":"Kemper C, Atkinson JP, Hourcade DE (2010) Properdin: emerging roles of a pattern-recognition molecule. Annu Rev Immunol 28:131\u2013155","journal-title":"Annu Rev Immunol"},{"key":"1_CR4","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1172\/JCI113780","volume":"82","author":"J Passwell","year":"1988","unstructured":"Passwell J, Schreiner GF, Nonaka M, Beuscher HU, Colten HR (1988) Local extrahepatic expression of complement genes C3, factor B, C2, and C4 is increased in murine lupus nephritis. J Clin Invest 82:1676\u20131684","journal-title":"J Clin Invest"},{"key":"1_CR5","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1146\/annurev-immunol-042617-053245","volume":"36","author":"EE West","year":"2018","unstructured":"West EE, Kolev M, Kemper C (2018) Complement and the regulation of T cell responses. Annu Rev Immunol 36:309\u2013338","journal-title":"Annu Rev Immunol"},{"key":"1_CR6","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1093\/oxfordjournals.jbchem.a135262","volume":"98","author":"T Matsuda","year":"1985","unstructured":"Matsuda T, Nagasawa S, Koide T, Koyama J (1985) Limited proteolysis of a chemically modified third component of human complement, C3, by cathepsin G of human leukocytes. J Biochem (Tokyo) 98:229\u2013236","journal-title":"J Biochem (Tokyo)"},{"key":"1_CR7","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.kint.2018.04.004","volume":"94","author":"ZD B\u00e9k\u00e1ssy","year":"2018","unstructured":"B\u00e9k\u00e1ssy ZD et al (2018) Aliskiren inhibits renin-mediated complement activation. Kidney Int 94:689\u2013700","journal-title":"Kidney Int"},{"key":"1_CR8","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nm1419","volume":"12","author":"M Huber-Lang","year":"2006","unstructured":"Huber-Lang M et al (2006) Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med 12:682\u2013687","journal-title":"Nat Med"},{"key":"1_CR9","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.ccell.2018.09.003","volume":"34","author":"TR Medler","year":"2018","unstructured":"Medler TR et al (2018) Complement C5a fosters squamous carcinogenesis and limits T cell response to chemotherapy. Cancer Cell 34:561\u2013578.e6","journal-title":"Cancer Cell"},{"key":"1_CR10","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/s41568-019-0210-0","volume":"19","author":"LT Roumenina","year":"2019","unstructured":"Roumenina LT, Daugan MV, Petitprez F, Saut\u00e8s-Fridman C, Fridman WH (2019) Context-dependent roles of complement in cancer. Nat Rev Cancer 19:698\u2013715","journal-title":"Nat Rev Cancer"},{"key":"1_CR11","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1096\/fj.201601306R","volume":"31","author":"S Yaseen","year":"2017","unstructured":"Yaseen S et al (2017) Lectin pathway effector enzyme mannan-binding lectin-associated serine protease-2 can activate native complement C3 in absence of C4 and\/or C2. FASEB J 31:2210\u20132219","journal-title":"FASEB J"},{"issue":"169","key":"1_CR12","doi-asserted-by":"publisher","first-page":"5489","DOI":"10.4049\/jimmunol.169.10.5489","volume":"1950","author":"M Gadjeva","year":"2002","unstructured":"Gadjeva M et al (2002) Macrophage-derived complement component C4 can restore humoral immunity in C4-deficient mice. J Immunol 1950(169):5489\u20135495","journal-title":"J Immunol"},{"key":"1_CR13","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1084\/jem.20041967","volume":"201","author":"PS Heeger","year":"2005","unstructured":"Heeger PS et al (2005) Decay-accelerating factor modulates induction of T cell immunity. J Exp Med 201:1523\u20131530","journal-title":"J Exp Med"},{"key":"1_CR14","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1182\/blood-2008-04-151068","volume":"112","author":"PN Lalli","year":"2008","unstructured":"Lalli PN et al (2008) Locally produced C5a binds to T cell\u2013expressed C5aR to enhance effector T-cell expansion by limiting antigen-induced apoptosis. Blood 112:1759\u20131766","journal-title":"Blood"},{"key":"1_CR15","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/nm0602-582","volume":"8","author":"JR Pratt","year":"2002","unstructured":"Pratt JR, Basheer SA, Sacks SH (2002) Local synthesis of complement component C3 regulates acute renal transplant rejection. Nat Med 8:582\u2013587","journal-title":"Nat Med"},{"key":"1_CR16","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/nri3761","volume":"14","author":"M Kolev","year":"2014","unstructured":"Kolev M, Friec GL, Kemper C (2014) Complement \u2014 tapping into new sites and effector systems. Nat Rev Immunol 14:811\u2013820","journal-title":"Nat Rev Immunol"},{"key":"1_CR17","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.immuni.2013.10.018","volume":"39","author":"MK Liszewski","year":"2013","unstructured":"Liszewski MK et al (2013) Intracellular complement activation sustains T cell homeostasis and mediates effector differentiation. Immunity 39:1143\u20131157","journal-title":"Immunity"},{"key":"1_CR18","doi-asserted-by":"publisher","first-page":"aad1210","DOI":"10.1126\/science.aad1210","volume":"352","author":"G Arbore","year":"2016","unstructured":"Arbore G et al (2016) T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4+ T cells. Science 352:aad1210","journal-title":"Science"},{"key":"1_CR19","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1126\/science.aao4555","volume":"360","author":"GS Ling","year":"2018","unstructured":"Ling GS et al (2018) C1q restrains autoimmunity and viral infection by regulating CD8 + T cell metabolism. Science 360:558\u2013563","journal-title":"Science"},{"key":"1_CR20","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3389\/fimmu.2019.00493","volume":"10","author":"M Kremlitzka","year":"2019","unstructured":"Kremlitzka M et al (2019) Interaction of serum-derived and internalized C3 with DNA in human B cells\u2014a potential involvement in regulation of gene transcription. Front Immunol 10:493","journal-title":"Front Immunol"},{"key":"1_CR21","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3389\/fimmu.2015.00257","volume":"6","author":"NS Merle","year":"2015","unstructured":"Merle NS, Noe R, Halbwachs-Mecarelli L, Fremeaux-Bacchi V, Roumenina LT (2015) Complement system part II: role in immunity. Front Immunol 6:257","journal-title":"Front Immunol"},{"key":"1_CR22","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/j.1749-6632.2009.04633.x","volume":"1173","author":"HD Pettigrew","year":"2009","unstructured":"Pettigrew HD, Teuber SS, Gershwin ME (2009) Clinical significance of complement deficiencies. Ann N Y Acad Sci 1173:108\u2013123","journal-title":"Ann N Y Acad Sci"},{"key":"1_CR23","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.ajhg.2011.05.011","volume":"88","author":"SE Degn","year":"2011","unstructured":"Degn SE, Jensenius JC, Thiel S (2011) Disease-causing mutations in genes of the complement system. Am J Hum Genet 88:689\u2013705","journal-title":"Am J Hum Genet"},{"key":"1_CR24","first-page":"271","volume":"72","author":"J Rosain","year":"2014","unstructured":"Rosain J et al (2014) Complement deficiencies and human diseases. Ann Biol Clin (Paris) 72:271\u2013280","journal-title":"Ann Biol Clin (Paris)"},{"key":"1_CR25","doi-asserted-by":"publisher","first-page":"300","DOI":"10.2215\/CJN.00620117","volume":"13","author":"V Brocklebank","year":"2018","unstructured":"Brocklebank V, Wood KM, Kavanagh D (2018) Thrombotic Microangiopathy and the kidney. Clin J Am Soc Nephrol 13:300\u2013317","journal-title":"Clin J Am Soc Nephrol"},{"key":"1_CR26","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41581-018-0107-2","volume":"15","author":"RJH Smith","year":"2019","unstructured":"Smith RJH et al (2019) C3 glomerulopathy\u2014understanding a rare complement-driven renal disease. Nat Rev Nephrol 15:129\u2013143","journal-title":"Nat Rev Nephrol"},{"key":"1_CR27","doi-asserted-by":"publisher","first-page":"886","DOI":"10.3389\/fimmu.2019.00886","volume":"10","author":"F Corvillo","year":"2019","unstructured":"Corvillo F et al (2019) Nephritic factors: an overview of classification, diagnostic tools and clinical associations. Front Immunol 10:886","journal-title":"Front Immunol"},{"key":"1_CR28","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1681\/ASN.2016030343","volume":"28","author":"MC Marinozzi","year":"2017","unstructured":"Marinozzi MC et al (2017) Anti-factor B and anti-C3b autoantibodies in C3 Glomerulopathy and Ig-associated Membranoproliferative GN. J Am Soc Nephrol 28:1603\u20131613","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"1_CR29","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1681\/ASN.2019080851","volume":"31","author":"S Chauvet","year":"2020","unstructured":"Chauvet S et al (2020) Anti-factor B antibodies and acute Postinfectious GN in children. J Am Soc Nephrol 31(4):829\u2013840. https:\/\/doi.org\/10.1681\/ASN.2019080851","journal-title":"J Am Soc Nephrol"},{"key":"1_CR30","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3389\/fimmu.2019.00064","volume":"10","author":"VV Vasilev","year":"2019","unstructured":"Vasilev VV et al (2019) Autoantibodies against C3b\u2014functional consequences and disease relevance. Front Immunol 10:64","journal-title":"Front Immunol"},{"key":"1_CR31","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1182\/blood-2016-08-737163","volume":"129","author":"S Chauvet","year":"2017","unstructured":"Chauvet S et al (2017) Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy\u2013associated C3 glomerulopathy. Blood 129:1437\u20131447","journal-title":"Blood"},{"key":"1_CR32","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1681\/ASN.2015040385","volume":"27","author":"F Bu","year":"2016","unstructured":"Bu F et al (2016) High-throughput genetic testing for thrombotic Microangiopathies and C3 Glomerulopathies. J Am Soc Nephrol 27:1245\u20131253","journal-title":"J Am Soc Nephrol"},{"key":"1_CR33","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.4049\/jimmunol.1701695","volume":"200","author":"AJ Osborne","year":"2018","unstructured":"Osborne AJ et al (2018) Statistical validation of rare complement variants provides insights into the molecular basis of atypical hemolytic uremic syndrome and C3 Glomerulopathy. J Immunol 200:2464\u20132478","journal-title":"J Immunol"},{"key":"1_CR34","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1080\/08916930701510673","volume":"40","author":"L Truedsson","year":"2007","unstructured":"Truedsson L, Bengtsson AA, Sturfelt G (2007) Complement deficiencies and systemic lupus erythematosus. Autoimmunity 40:560\u2013566","journal-title":"Autoimmunity"},{"key":"1_CR35","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1084\/jem.192.3.359","volume":"192","author":"PR Taylor","year":"2000","unstructured":"Taylor PR et al (2000) A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo. J Exp Med 192:359\u2013366","journal-title":"J Exp Med"},{"key":"1_CR36","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1146\/annurev.immunol.22.012703.104549","volume":"22","author":"AP Manderson","year":"2004","unstructured":"Manderson AP, Botto M, Walport MJ (2004) The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol 22:431\u2013456","journal-title":"Annu Rev Immunol"},{"key":"1_CR37","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/nrrheum.2017.125","volume":"13","author":"LA Trouw","year":"2017","unstructured":"Trouw LA, Pickering MC, Blom AM (2017) The complement system as a potential therapeutic target in rheumatic disease. Nat Rev Rheumatol 13:538\u2013547","journal-title":"Nat Rev Rheumatol"},{"key":"1_CR38","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.molimm.2013.05.009","volume":"56","author":"M-A Dragon-Durey","year":"2013","unstructured":"Dragon-Durey M-A, Blanc C, Marinozzi MC, van Schaarenburg RA, Trouw LA (2013) Autoantibodies against complement components and functional consequences. Mol Immunol 56:213\u2013221","journal-title":"Mol Immunol"},{"key":"1_CR39","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1136\/annrheumdis-2014-205287","volume":"73","author":"J Leffler","year":"2014","unstructured":"Leffler J, Bengtsson AA, Blom AM (2014) The complement system in systemic lupus erythematosus: an update. Ann Rheum Dis 73:1601\u20131606","journal-title":"Ann Rheum Dis"},{"key":"1_CR40","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1002\/art.1780341209","volume":"34","author":"JP Brodeur","year":"1991","unstructured":"Brodeur JP, Ruddy S, Schwartz LB, Moxley G (1991) Synovial fluid levels of complement SC5b-9 and fragment bb are elevated in patients with rheumatoid arthritis. Arthritis Rheum 34:1531\u20131537","journal-title":"Arthritis Rheum"},{"key":"1_CR41","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/nrrheum.2017.15","volume":"13","author":"LA Trouw","year":"2017","unstructured":"Trouw LA, Rispens T, Toes REM (2017) Beyond citrullination: other post-translational protein modifications in rheumatoid arthritis. Nat Rev Rheumatol 13:331\u2013339","journal-title":"Nat Rev Rheumatol"},{"key":"1_CR42","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S1074-7613(02)00275-3","volume":"16","author":"H Ji","year":"2002","unstructured":"Ji H et al (2002) Arthritis critically dependent on innate immune system players. Immunity 16:157\u2013168","journal-title":"Immunity"},{"key":"1_CR43","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/ki.2012.313","volume":"83","author":"S-J Gou","year":"2013","unstructured":"Gou S-J, Yuan J, Chen M, Yu F, Zhao M-H (2013) Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. Kidney Int 83:129\u2013137","journal-title":"Kidney Int"},{"key":"1_CR44","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1007\/s10875-008-9268-2","volume":"29","author":"G Xing","year":"2008","unstructured":"Xing G et al (2008) Complement activation is involved in renal damage in human Antineutrophil cytoplasmic autoantibody associated Pauci-immune Vasculitis. J Clin Immunol 29:282","journal-title":"J Clin Immunol"},{"issue":"188","key":"1_CR45","doi-asserted-by":"publisher","first-page":"3522","DOI":"10.4049\/jimmunol.1102404","volume":"1950","author":"J Leffler","year":"2012","unstructured":"Leffler J et al (2012) Neutrophil extracellular traps that are not degraded in systemic lupus erythematosus activate complement exacerbating the disease. J Immunol 1950(188):3522\u20133531","journal-title":"J Immunol"},{"key":"1_CR46","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/nri.2017.97","volume":"18","author":"ES Reis","year":"2018","unstructured":"Reis ES, Mastellos DC, Ricklin D, Mantovani A, Lambris JD (2018) Complement in cancer: untangling an intricate relationship. Nat Rev Immunol 18:5\u201318","journal-title":"Nat Rev Immunol"},{"key":"1_CR47","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1158\/2326-6066.CIR-18-0891","volume":"7","author":"LT Roumenina","year":"2019","unstructured":"Roumenina LT et al (2019) Tumor cells hijack macrophage-produced complement C1q to promote tumor growth. Cancer Immunol Res 7:1091\u20131105","journal-title":"Cancer Immunol Res"},{"key":"1_CR48","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.cell.2015.01.004","volume":"160","author":"E Bonavita","year":"2015","unstructured":"Bonavita E et al (2015) PTX3 is an extrinsic oncosuppressor regulating complement-dependent inflammation in cancer. Cell 160:700\u2013714","journal-title":"Cell"},{"issue":"196","key":"1_CR49","doi-asserted-by":"publisher","first-page":"4783","DOI":"10.4049\/jimmunol.1600210","volume":"1950","author":"JA Nabizadeh","year":"2016","unstructured":"Nabizadeh JA et al (2016) The complement C3a receptor contributes to melanoma tumorigenesis by inhibiting neutrophil and CD4+ T cell responses. J Immunol 1950(196):4783\u20134792","journal-title":"J Immunol"},{"key":"1_CR50","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1158\/2326-6066.CIR-13-0173","volume":"2","author":"V Janelle","year":"2014","unstructured":"Janelle V et al (2014) Transient complement inhibition promotes a tumor-specific immune response through the implication of natural killer cells. Cancer Immunol Res 2:200\u2013206","journal-title":"Cancer Immunol Res"},{"key":"1_CR51","doi-asserted-by":"publisher","first-page":"10346","DOI":"10.1038\/ncomms10346","volume":"7","author":"R Bulla","year":"2016","unstructured":"Bulla R et al (2016) C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation. Nat Commun 7:10346","journal-title":"Nat Commun"},{"key":"1_CR52","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1038\/ni.3858","volume":"18","author":"G Hajishengallis","year":"2017","unstructured":"Hajishengallis G, Reis ES, Mastellos DC, Ricklin D, Lambris JD (2017) Novel mechanisms and functions of complement. Nat Immunol 18:1288\u20131298","journal-title":"Nat Immunol"},{"key":"1_CR53","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3389\/fimmu.2019.00362","volume":"10","author":"SM Carpanini","year":"2019","unstructured":"Carpanini SM, Torvell M, Morgan BP (2019) Therapeutic inhibition of the complement system in diseases of the central nervous system. Front Immunol 10:362","journal-title":"Front Immunol"},{"key":"1_CR54","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.cell.2007.10.036","volume":"131","author":"B Stevens","year":"2007","unstructured":"Stevens B et al (2007) The classical complement cascade mediates CNS synapse elimination. Cell 131:1164\u20131178","journal-title":"Cell"},{"key":"1_CR55","doi-asserted-by":"publisher","first-page":"13029","DOI":"10.1523\/JNEUROSCI.1698-15.2015","volume":"35","author":"Q Shi","year":"2015","unstructured":"Shi Q et al (2015) Complement C3-deficient mice fail to display age-related hippocampal decline. J Neurosci 35:13029\u201313042","journal-title":"J Neurosci"},{"key":"1_CR56","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/nrn3880","volume":"16","author":"FL Heppner","year":"2015","unstructured":"Heppner FL, Ransohoff RM, Becher B (2015) Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci 16:358\u2013372","journal-title":"Nat Rev Neurosci"},{"key":"1_CR57","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.smim.2016.03.015","volume":"28","author":"FH Brennan","year":"2016","unstructured":"Brennan FH, Lee JD, Ruitenberg MJ, Woodruff TM (2016) Therapeutic targeting of complement to modify disease course and improve outcomes in neurological conditions. Semin Immunol 28:292\u2013308","journal-title":"Semin Immunol"},{"key":"1_CR58","doi-asserted-by":"publisher","first-page":"175909141668787","DOI":"10.1177\/1759091416687871","volume":"9","author":"MX Hernandez","year":"2017","unstructured":"Hernandez MX, Namiranian P, Nguyen E, Fonseca MI, Tenner AJ (2017) C5a increases the injury to primary neurons elicited by Fibrillar amyloid Beta. ASN Neuro 9:1759091416687871","journal-title":"ASN Neuro"},{"key":"1_CR59","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1038\/ng.439","volume":"41","author":"J-C Lambert","year":"2009","unstructured":"Lambert J-C et al (2009) Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer\u2019s disease. Nat Genet 41:1094\u20131099","journal-title":"Nat Genet"},{"key":"1_CR60","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1111\/j.1471-4159.2008.05558.x","volume":"106","author":"J Zhou","year":"2008","unstructured":"Zhou J, Fonseca MI, Pisalyaput K, Tenner AJ (2008) Complement C3 and C4 expression in C1q sufficient and deficient mouse models of Alzheimer\u2019s disease. J Neurochem 106:2080\u20132092","journal-title":"J Neurochem"},{"key":"1_CR61","doi-asserted-by":"publisher","first-page":"6333","DOI":"10.1523\/JNEUROSCI.0829-08.2008","volume":"28","author":"M Maier","year":"2008","unstructured":"Maier M et al (2008) Complement C3 deficiency leads to accelerated amyloid \u03b2 plaque deposition and neurodegeneration and modulation of the microglia\/macrophage phenotype in amyloid precursor protein transgenic mice. J Neurosci 28:6333\u20136341","journal-title":"J Neurosci"},{"key":"1_CR62","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.nbd.2011.01.002","volume":"42","author":"M Sta","year":"2011","unstructured":"Sta M et al (2011) Innate and adaptive immunity in amyotrophic lateral sclerosis: evidence of complement activation. Neurobiol Dis 42:211\u2013220","journal-title":"Neurobiol Dis"},{"key":"1_CR63","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jneuroim.2014.09.005","volume":"276","author":"S Mantovani","year":"2014","unstructured":"Mantovani S et al (2014) Elevation of the terminal complement activation products C5a and C5b-9 in ALS patient blood. J Neuroimmunol 276:213\u2013218","journal-title":"J Neuroimmunol"},{"key":"1_CR64","doi-asserted-by":"publisher","first-page":"E4385","DOI":"10.1073\/pnas.1318309110","volume":"110","author":"CS Lobsiger","year":"2013","unstructured":"Lobsiger CS et al (2013) C1q induction and global complement pathway activation do not contribute to ALS toxicity in mutant SOD1 mice. Proc Natl Acad Sci U S A 110:E4385\u2013E4392","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1_CR65","doi-asserted-by":"publisher","first-page":"20960","DOI":"10.1073\/pnas.0911405106","volume":"106","author":"IM Chiu","year":"2009","unstructured":"Chiu IM et al (2009) Activation of innate and humoral immunity in the peripheral nervous system of ALS transgenic mice. Proc Natl Acad Sci U S A 106:20960\u201320965","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1_CR66","doi-asserted-by":"publisher","first-page":"8727","DOI":"10.4049\/jimmunol.181.12.8727","volume":"181","author":"TM Woodruff","year":"2008","unstructured":"Woodruff TM et al (2008) The complement factor C5a contributes to pathology in a rat model of amyotrophic lateral sclerosis. J Immunol 181:8727\u20138734","journal-title":"J Immunol"},{"key":"1_CR67","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1111\/bph.13730","volume":"174","author":"JD Lee","year":"2017","unstructured":"Lee JD et al (2017) Pharmacological inhibition of complement C5a-C5a1 receptor signalling ameliorates disease pathology in the hSOD1G93A mouse model of amyotrophic lateral sclerosis. Br J Pharmacol 174:689\u2013699","journal-title":"Br J Pharmacol"},{"key":"1_CR68","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1006\/exnr.1999.7170","volume":"159","author":"SK Singhrao","year":"1999","unstructured":"Singhrao SK, Neal JW, Morgan BP, Gasque P (1999) Increased complement biosynthesis by microglia and complement activation on neurons in Huntington\u2019s disease. Exp Neurol 159:362\u2013376","journal-title":"Exp Neurol"},{"key":"1_CR69","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1742-2094-3-29","volume":"3","author":"DA Loeffler","year":"2006","unstructured":"Loeffler DA, Camp DM, Conant SB (2006) Complement activation in the Parkinson\u2019s disease substantia nigra: an immunocytochemical study. J Neuroinflammation 3:29","journal-title":"J Neuroinflammation"},{"key":"1_CR70","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","volume":"12","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE et al (2016) Myasthenia gravis\u2014autoantibody characteristics and their implications for therapy. Nat Rev Neurol 12:259\u2013268","journal-title":"Nat Rev Neurol"},{"key":"1_CR71","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/nyas.13522","volume":"1412","author":"JF Howard","year":"2018","unstructured":"Howard JF (2018) Myasthenia gravis: the role of complement at the neuromuscular junction. Ann N Y Acad Sci 1412:113\u2013128","journal-title":"Ann N Y Acad Sci"},{"key":"1_CR72","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1212\/WNL.43.6.1167","volume":"43","author":"S Nakano","year":"1993","unstructured":"Nakano S, Engel AG (1993) Myasthenia gravis: quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients. Neurology 43:1167\u20131172","journal-title":"Neurology"},{"key":"1_CR73","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1126\/science.1110359","volume":"308","author":"JL Haines","year":"2005","unstructured":"Haines JL et al (2005) Complement factor H variant increases the risk of age-related macular degeneration. Science 308:419\u2013421","journal-title":"Science"},{"key":"1_CR74","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1038\/ng.2741","volume":"45","author":"JM Seddon","year":"2013","unstructured":"Seddon JM et al (2013) Rare variants in CFI, C3 and C9 are associated with high risk of advanced age-related macular degeneration. Nat Genet 45:1366\u20131370","journal-title":"Nat Genet"},{"key":"1_CR75","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/nature10449","volume":"478","author":"D Weismann","year":"2011","unstructured":"Weismann D et al (2011) Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature 478:76\u201381","journal-title":"Nature"},{"key":"1_CR76","doi-asserted-by":"publisher","first-page":"13757","DOI":"10.1073\/pnas.1121309109","volume":"109","author":"PX Shaw","year":"2012","unstructured":"Shaw PX et al (2012) Complement factor H genotypes impact risk of age-related macular degeneration by interaction with oxidized phospholipids. Proc Natl Acad Sci U S A 109:13757\u201313762","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1_CR77","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.imbio.2015.11.007","volume":"221","author":"M van Lookeren Campagne","year":"2016","unstructured":"van Lookeren Campagne M, Strauss EC, Yaspan BL (2016) Age-related macular degeneration: complement in action. Immunobiology 221:733\u2013739","journal-title":"Immunobiology"},{"key":"1_CR78","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/ng1890","volume":"38","author":"AE Hughes","year":"2006","unstructured":"Hughes AE et al (2006) A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration. Nat Genet 38:1173\u20131177","journal-title":"Nat Genet"},{"key":"1_CR79","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/s41467-020-14499-3","volume":"11","author":"V Cipriani","year":"2020","unstructured":"Cipriani V et al (2020) Increased circulating levels of factor H-related protein 4 are strongly associated with age-related macular degeneration. Nat Commun 11:778","journal-title":"Nat Commun"},{"key":"1_CR80","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1182\/blood-2014-02-522128","volume":"124","author":"RA Brodsky","year":"2014","unstructured":"Brodsky RA (2014) Paroxysmal nocturnal hemoglobinuria. Blood 124:2804\u20132811","journal-title":"Blood"},{"key":"1_CR81","doi-asserted-by":"crossref","unstructured":"Griffin M et al (2019) Significant hemolysis is not required for thrombosis in paroxysmal nocturnal hemoglobinuria. Haematologica 104:94\u201396","DOI":"10.3324\/haematol.2018.198846"},{"key":"1_CR82","doi-asserted-by":"publisher","first-page":"4094","DOI":"10.1182\/blood-2008-11-189944","volume":"113","author":"AM Risitano","year":"2009","unstructured":"Risitano AM et al (2009) Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood 113:4094\u20134100","journal-title":"Blood"},{"key":"1_CR83","doi-asserted-by":"publisher","first-page":"567","DOI":"10.3324\/haematol.2009.007229","volume":"95","author":"A Hill","year":"2010","unstructured":"Hill A et al (2010) Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization. Haematologica 95:567\u2013573","journal-title":"Haematologica"},{"key":"1_CR84","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1182\/blood-2015-02-625871","volume":"126","author":"Z Lin","year":"2015","unstructured":"Lin Z et al (2015) Complement C3dg-mediated erythrophagocytosis: implications for paroxysmal nocturnal hemoglobinuria. Blood 126:891\u2013894","journal-title":"Blood"},{"key":"1_CR85","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1172\/JCI116706","volume":"92","author":"RH Wang","year":"1993","unstructured":"Wang RH, Phillips G, Medof ME, Mold C (1993) Activation of the alternative complement pathway by exposure of phosphatidylethanolamine and phosphatidylserine on erythrocytes from sickle cell disease patients. J Clin Invest 92:1326\u20131335","journal-title":"J Clin Invest"},{"key":"1_CR86","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1006\/clin.1995.1131","volume":"76","author":"C Mold","year":"1995","unstructured":"Mold C, Tamerius JD, Phillips G (1995) Complement activation during painful crisis in sickle cell anemia. Clin Immunol Immunopathol 76:314\u2013320","journal-title":"Clin Immunol Immunopathol"},{"key":"1_CR87","doi-asserted-by":"publisher","first-page":"919","DOI":"10.3324\/haematol.2018.198622","volume":"104","author":"E Lombardi","year":"2019","unstructured":"Lombardi E et al (2019) Factor H interferes with the adhesion of sickle red cells to vascular endothelium: a novel disease-modulating molecule. Haematologica 104:919\u2013928","journal-title":"Haematologica"},{"issue":"5","key":"1_CR88","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1002\/ajh.25742","volume":"95","author":"LT Roumenina","year":"2020","unstructured":"Roumenina LT et al (2020) Complement activation in sickle cell disease: dependence on cell density, hemolysis and modulation by hydroxyurea therapy. Am J Hematol 95(5):456\u2013464. https:\/\/doi.org\/10.1002\/ajh.25742","journal-title":"Am J Hematol"},{"issue":"12","key":"1_CR89","doi-asserted-by":"publisher","first-page":"e96910","DOI":"10.1172\/jci.insight.96910","volume":"3","author":"NS Merle","year":"2018","unstructured":"Merle NS et al (2018) Intravascular hemolysis activates complement via cell-free heme and heme-loaded microvesicles. JCI Insight 3(12):e96910","journal-title":"JCI Insight"},{"key":"1_CR90","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/ajh.25384","volume":"94","author":"GM Vercellotti","year":"2019","unstructured":"Vercellotti GM et al (2019) Critical role of C5a in sickle cell disease. Am J Hematol 94:327\u2013337","journal-title":"Am J Hematol"},{"key":"1_CR91","doi-asserted-by":"publisher","first-page":"6280","DOI":"10.1073\/pnas.1814797116","volume":"116","author":"NS Merle","year":"2019","unstructured":"Merle NS et al (2019) P-selectin drives complement attack on endothelium during intravascular hemolysis in TLR-4\/heme-dependent manner. Proc Natl Acad Sci 116:6280\u20136285","journal-title":"Proc Natl Acad Sci"},{"key":"1_CR92","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.tracli.2019.02.008","volume":"26","author":"NS Merle","year":"2019","unstructured":"Merle NS, Boudhabhay I, Leon J, Fremeaux-Bacchi V, Roumenina LT (2019) Complement activation during intravascular hemolysis: implication for sickle cell disease and hemolytic transfusion reactions. Transfus Clin Biol 26:116\u2013124","journal-title":"Transfus Clin Biol"},{"key":"1_CR93","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/0091-6749(89)90082-1","volume":"83","author":"K Bork","year":"1989","unstructured":"Bork K, Witzke G (1989) Long-term prophylaxis with C1-inhibitor (C1 INH) concentrate in patients with recurrent angioedema caused by hereditary and acquired C1-inhibitor deficiency. J Allergy Clin Immunol 83:677\u2013682","journal-title":"J Allergy Clin Immunol"},{"key":"1_CR94","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1056\/NEJMoa031688","volume":"350","author":"P Hillmen","year":"2004","unstructured":"Hillmen P et al (2004) Effect of Eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 350:552\u2013559","journal-title":"N Engl J Med"},{"key":"1_CR95","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1056\/NEJMoa061648","volume":"355","author":"P Hillmen","year":"2006","unstructured":"Hillmen P et al (2006) The complement inhibitor Eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 355:1233\u20131243","journal-title":"N Engl J Med"},{"key":"1_CR96","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1182\/blood-2007-06-094136","volume":"111","author":"RA Brodsky","year":"2008","unstructured":"Brodsky RA et al (2008) Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 111:1840\u20131847","journal-title":"Blood"},{"key":"1_CR97","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/bjh.12347","volume":"162","author":"P Hillmen","year":"2013","unstructured":"Hillmen P et al (2013) Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 162:62\u201373","journal-title":"Br J Haematol"},{"key":"1_CR98","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1056\/NEJMc0809959","volume":"360","author":"RA Gruppo","year":"2009","unstructured":"Gruppo RA, Rother RP (2009) Eculizumab for congenital atypical hemolytic\u2013uremic syndrome. N Engl J Med 360:544\u2013546","journal-title":"N Engl J Med"},{"key":"1_CR99","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","volume":"368","author":"CM Legendre","year":"2013","unstructured":"Legendre CM et al (2013) Terminal complement inhibitor Eculizumab in atypical hemolytic\u2013uremic syndrome. N Engl J Med 368:2169\u20132181","journal-title":"N Engl J Med"},{"key":"1_CR100","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","volume":"89","author":"LA Greenbaum","year":"2016","unstructured":"Greenbaum LA et al (2016) Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int 89:701\u2013711","journal-title":"Kidney Int"},{"key":"1_CR101","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1007\/s00467-018-3903-9","volume":"33","author":"L Percheron","year":"2018","unstructured":"Percheron L et al (2018) Eculizumab treatment in severe pediatric STEC-HUS: a multicenter retrospective study. Pediatr Nephrol 33:1385\u20131394","journal-title":"Pediatr Nephrol"},{"key":"1_CR102","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.placenta.2012.11.014","volume":"34","author":"RM Burwick","year":"2013","unstructured":"Burwick RM, Feinberg BB (2013) Eculizumab for the treatment of preeclampsia\/HELLP syndrome. Placenta 34:201\u2013203","journal-title":"Placenta"},{"key":"1_CR103","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1097\/TP.0000000000000601","volume":"99","author":"FS de Fontbrune","year":"2015","unstructured":"de Fontbrune FS et al (2015) Use of Eculizumab in patients with allogeneic stem cell transplant-associated thrombotic Microangiopathy: a study from the SFGM-TC. Transplantation 99:1953\u20131959","journal-title":"Transplantation"},{"key":"1_CR104","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","volume":"68","author":"F Fakhouri","year":"2016","unstructured":"Fakhouri F et al (2016) Terminal complement inhibitor Eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial. Am J Kidney Dis 68:84\u201393","journal-title":"Am J Kidney Dis"},{"key":"1_CR105","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1056\/NEJMoa1311084","volume":"370","author":"J Nishimura","year":"2014","unstructured":"Nishimura J et al (2014) Genetic variants in C5 and poor response to Eculizumab. N Engl J Med 370:632\u2013639","journal-title":"N Engl J Med"},{"key":"1_CR106","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.3389\/fimmu.2019.01157","volume":"10","author":"AM Risitano","year":"2019","unstructured":"Risitano AM et al (2019) Anti-complement treatment for paroxysmal nocturnal hemoglobinuria: time for proximal complement inhibition? A position paper from the SAAWP of the EBMT. Front Immunol 10:1157","journal-title":"Front Immunol"},{"key":"1_CR107","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.4049\/jimmunol.164.3.1379","volume":"164","author":"N Rawal","year":"2000","unstructured":"Rawal N, Pangburn MK (2000) Functional role of the noncatalytic subunit of complement C5 convertase. J Immunol 164:1379\u20131385","journal-title":"J Immunol"},{"key":"1_CR108","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1053\/j.ajkd.2015.04.010","volume":"66","author":"G Ardissino","year":"2015","unstructured":"Ardissino G et al (2015) Discontinuation of Eculizumab treatment in atypical hemolytic uremic syndrome: an update. Am J Kidney Dis 66:172\u2013173","journal-title":"Am J Kidney Dis"},{"key":"1_CR109","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1182\/blood-2017-02-770214","volume":"130","author":"SA Merrill","year":"2017","unstructured":"Merrill SA et al (2017) Eculizumab cessation in atypical hemolytic uremic syndrome. Blood 130:368\u2013372","journal-title":"Blood"},{"key":"1_CR110","doi-asserted-by":"publisher","first-page":"50","DOI":"10.2215\/CJN.06440616","volume":"12","author":"F Fakhouri","year":"2017","unstructured":"Fakhouri F et al (2017) Pathogenic variants in complement genes and risk of atypical hemolytic uremic syndrome relapse after Eculizumab discontinuation. Clin J Am Soc Nephrol 12:50\u201359","journal-title":"Clin J Am Soc Nephrol"},{"key":"1_CR111","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/nrneph.2017.156","volume":"14","author":"D Ricklin","year":"2018","unstructured":"Ricklin D, Mastellos DC, Reis ES, Lambris JD (2018) The renaissance of complement therapeutics. Nat Rev Nephrol 14:26\u201347","journal-title":"Nat Rev Nephrol"},{"key":"1_CR112","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.3389\/fimmu.2019.02306","volume":"10","author":"VS Tatapudi","year":"2019","unstructured":"Tatapudi VS, Montgomery RA (2019) Therapeutic modulation of the complement system in kidney transplantation: clinical indications and emerging drug leads. Front Immunol 10:2306","journal-title":"Front Immunol"},{"issue":"5","key":"1_CR113","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1111\/ajt.13663","volume":"16","author":"D Viglietti","year":"2016","unstructured":"Viglietti D et al (2016) C1-inhibitor in acute antibody-mediated rejection non-responsive to conventional therapy in kidney transplant recipients: a pilot study. Am J Transplant 16(5):1596\u20131603. https:\/\/doi.org\/10.1111\/ajt.13663","journal-title":"Am J Transplant"},{"key":"1_CR114","doi-asserted-by":"publisher","first-page":"3468","DOI":"10.1111\/ajt.13871","volume":"16","author":"RA Montgomery","year":"2016","unstructured":"Montgomery RA et al (2016) Plasma-derived C1 esterase inhibitor for acute antibody-mediated rejection following kidney transplantation: results of a randomized double-blind placebo-controlled pilot study. Am J Transplant 16:3468\u20133478","journal-title":"Am J Transplant"},{"key":"1_CR115","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1111\/j.1600-6143.2011.03757.x","volume":"11","author":"MD Stegall","year":"2011","unstructured":"Stegall MD et al (2011) Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 11:2405\u20132413","journal-title":"Am J Transplant"},{"key":"1_CR116","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.3389\/fimmu.2019.01007","volume":"10","author":"DH Park","year":"2019","unstructured":"Park DH, Connor KM, Lambris JD (2019) The challenges and promise of complement therapeutics for ocular diseases. Front Immunol 10:1007","journal-title":"Front Immunol"},{"key":"1_CR117","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMoa1900866","volume":"381","author":"SJ Pittock","year":"2019","unstructured":"Pittock SJ et al (2019) Eculizumab in Aquaporin-4\u2013positive Neuromyelitis Optica Spectrum disorder. N Engl J Med 381:614\u2013625","journal-title":"N Engl J Med"},{"key":"1_CR118","doi-asserted-by":"publisher","first-page":"543","DOI":"10.3389\/fimmu.2019.00543","volume":"10","author":"E Karasu","year":"2019","unstructured":"Karasu E, Nilsson B, K\u00f6hl J, Lambris JD, Huber-Lang M (2019) Targeting complement pathways in Polytrauma- and sepsis-induced multiple-organ dysfunction. Front Immunol 10:543","journal-title":"Front Immunol"},{"key":"1_CR119","doi-asserted-by":"publisher","first-page":"672","DOI":"10.3389\/fimmu.2019.00672","volume":"10","author":"JM Thurman","year":"2019","unstructured":"Thurman JM, Yapa R (2019) Complement therapeutics in autoimmune disease. Front Immunol 10:672","journal-title":"Front Immunol"},{"key":"1_CR120","first-page":"2286","volume":"54","author":"MC Pickering","year":"2015","unstructured":"Pickering MC et al (2015) Eculizumab as rescue therapy in severe resistant lupus nephritis. Rheumatology (Oxford) 54:2286\u20132288","journal-title":"Rheumatology (Oxford)"},{"key":"1_CR121","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1182\/bloodadvances.2018019596","volume":"2","author":"MH Park","year":"2018","unstructured":"Park MH, Caselman N, Ulmer S, Weitz IC (2018) Complement-mediated thrombotic microangiopathy associated with lupus nephritis. Blood Adv 2:2090\u20132094","journal-title":"Blood Adv"},{"key":"1_CR122","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"JF Howard","year":"2017","unstructured":"Howard JF et al (2017) Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16:976\u2013986","journal-title":"Lancet Neurol"},{"key":"1_CR123","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1056\/NEJMc0910965","volume":"362","author":"BE Lonze","year":"2010","unstructured":"Lonze BE, Singer AL, Montgomery RA (2010) Eculizumab and renal transplantation in a patient with CAPS. N Engl J Med 362:1744\u20131745","journal-title":"N Engl J Med"},{"key":"1_CR124","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1002\/art.34440","volume":"64","author":"I Shapira","year":"2012","unstructured":"Shapira I, Andrade D, Allen SL, Salmon JE (2012) Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab. Arthritis Rheum 64:2719\u20132723","journal-title":"Arthritis Rheum"},{"key":"1_CR125","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1681\/ASN.2016111179","volume":"28","author":"DRW Jayne","year":"2017","unstructured":"Jayne DRW et al (2017) Randomized trial of C5a receptor inhibitor Avacopan in ANCA-associated Vasculitis. J Am Soc Nephrol 28:2756\u20132767","journal-title":"J Am Soc Nephrol"},{"key":"1_CR126","doi-asserted-by":"publisher","first-page":"774","DOI":"10.3389\/fimmu.2019.00774","volume":"10","author":"R Pio","year":"2019","unstructured":"Pio R, Ajona D, Ortiz-Espinosa S, Mantovani A, Lambris JD (2019) Complementing the cancer-immunity cycle. Front Immunol 10:774","journal-title":"Front Immunol"},{"key":"1_CR127","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jinf.2019.11.015","volume":"80","author":"PE Crew","year":"2020","unstructured":"Crew PE et al (2020) Antibiotic prophylaxis in vaccinated eculizumab recipients who developed meningococcal disease. J Infect 80:350\u2013371","journal-title":"J Infect"},{"key":"1_CR128","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.3389\/fimmu.2019.02539","volume":"10","author":"M Mohebnasab","year":"2019","unstructured":"Mohebnasab M et al (2019) Current and future approaches for monitoring responses to anti-complement therapeutics. Front Immunol 10:2539","journal-title":"Front Immunol"},{"key":"1_CR129","doi-asserted-by":"publisher","DOI":"10.1111\/aji.13202","volume":"83","author":"Y He","year":"2020","unstructured":"He Y et al (2020) Normal range of complement components during pregnancy: a prospective study. Am J Reprod Immunol 83:e13202","journal-title":"Am J Reprod Immunol"},{"key":"1_CR130","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.3389\/fimmu.2018.02237","volume":"9","author":"KN Ekdahl","year":"2018","unstructured":"Ekdahl KN et al (2018) Interpretation of serological complement biomarkers in disease. Front Immunol 9:2237","journal-title":"Front Immunol"},{"key":"1_CR131","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.molimm.2017.05.021","volume":"89","author":"PH Nilsson","year":"2017","unstructured":"Nilsson PH et al (2017) Eculizumab-C5 complexes express a C5a neoepitope in vivo: consequences for interpretation of patient complement analyses. Mol Immunol 89:111\u2013114","journal-title":"Mol Immunol"},{"issue":"113","key":"1_CR132","doi-asserted-by":"publisher","first-page":"348","DOI":"10.4049\/jimmunol.113.1.348","volume":"1950","author":"TA Platts-Mills","year":"1974","unstructured":"Platts-Mills TA, Ishizaka K (1974) Activation of the alternate pathway of human complements by rabbit cells. J Immunol 1950(113):348\u2013358","journal-title":"J Immunol"},{"key":"1_CR133","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1093\/clinchem\/41.4.586","volume":"41","author":"S Yamamoto","year":"1995","unstructured":"Yamamoto S et al (1995) Automated homogeneous liposome-based assay system for total complement activity. Clin Chem 41:586\u2013590","journal-title":"Clin Chem"},{"key":"1_CR134","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jim.2004.11.016","volume":"296","author":"MA Seelen","year":"2005","unstructured":"Seelen MA et al (2005) Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. J Immunol Methods 296:187\u2013198","journal-title":"J Immunol Methods"},{"key":"1_CR135","doi-asserted-by":"publisher","first-page":"3637","DOI":"10.1182\/blood-2015-02-629683","volume":"125","author":"E Gavriilaki","year":"2015","unstructured":"Gavriilaki E et al (2015) Modified ham test for atypical hemolytic uremic syndrome. Blood 125:3637\u20133646","journal-title":"Blood"},{"key":"1_CR136","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1182\/blood-2014-02-558296","volume":"124","author":"M Noris","year":"2014","unstructured":"Noris M et al (2014) Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood 124:1715\u20131726","journal-title":"Blood"},{"key":"1_CR137","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.2215\/CJN.05830519","volume":"14","author":"M Palomo","year":"2019","unstructured":"Palomo M et al (2019) Complement activation and thrombotic Microangiopathies. Clin J Am Soc Nephrol 14:1719\u20131732","journal-title":"Clin J Am Soc Nephrol"},{"issue":"116","key":"1_CR138","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4049\/jimmunol.116.1.1","volume":"1950","author":"MR Daha","year":"1976","unstructured":"Daha MR, Fearon DT, Austen KF (1976) C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase. J Immunol 1950(116):1\u20137","journal-title":"J Immunol"},{"key":"1_CR139","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/ki.2012.63","volume":"82","author":"A Servais","year":"2012","unstructured":"Servais A et al (2012) Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 82:454\u2013464","journal-title":"Kidney Int"},{"key":"1_CR140","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/j.kint.2017.04.017","volume":"92","author":"M-C Marinozzi","year":"2017","unstructured":"Marinozzi M-C et al (2017) C5 nephritic factors drive the biological phenotype of C3 glomerulopathies. Kidney Int 92:1232\u20131241","journal-title":"Kidney Int"},{"key":"1_CR141","doi-asserted-by":"crossref","unstructured":"Halbwachs L, Leveill\u00e9 M, Lesavre P, Wattel S, Leibowitch J (1980) Nephritic factor of the classical pathway of complement: immunoglobulin G autoantibody directed against the classical pathway C3 convertase enzyme. J Clin Invest 65:1249\u20131256","DOI":"10.1172\/JCI109787"},{"key":"1_CR142","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1084\/jem.154.1.1","volume":"154","author":"I Gigli","year":"1981","unstructured":"Gigli I, Sorvillo J, Mecarelli-Halbwachs L, Leibowitch J (1981) Mechanism of action of the C4 nephritic factor. Deregulation of the classical pathway of C3 convertase. J Exp Med 154:1\u201312","journal-title":"J Exp Med"},{"key":"1_CR143","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1053\/j.ajkd.2017.07.004","volume":"70","author":"Y Zhang","year":"2017","unstructured":"Zhang Y et al (2017) C4 nephritic factors in C3 Glomerulopathy: a case series. Am J Kidney Dis 70:834\u2013843","journal-title":"Am J Kidney Dis"},{"key":"1_CR144","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1371\/journal.pgen.0030041","volume":"3","author":"PF Zipfel","year":"2007","unstructured":"Zipfel PF et al (2007) Deletion of complement factor H\u2013related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet 3:e41","journal-title":"PLoS Genet"},{"key":"1_CR145","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1136\/jmg.2008.064766","volume":"46","author":"M-A Dragon-Durey","year":"2009","unstructured":"Dragon-Durey M-A et al (2009) The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome. J Med Genet 46:447\u2013450","journal-title":"J Med Genet"},{"key":"1_CR146","doi-asserted-by":"crossref","unstructured":"Chen Q et al (2011) Combined C3b and factor B autoantibodies and MPGN type II. N Engl J Med 365:2340\u20132342\u00a0","DOI":"10.1056\/NEJMc1107484"},{"key":"1_CR147","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.molimm.2014.06.030","volume":"61","author":"AS Grumach","year":"2014","unstructured":"Grumach AS, Kirschfink M (2014) Are complement deficiencies really rare? Overview on prevalence, clinical importance and modern diagnostic approach. Mol Immunol 61:110\u2013117","journal-title":"Mol Immunol"},{"key":"1_CR148","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.3389\/fimmu.2019.01936","volume":"10","author":"C El Sissy","year":"2019","unstructured":"El Sissy C et al (2019) Clinical and genetic Spectrum of a large cohort with Total and sub-total complement deficiencies. Front Immunol 10:1936","journal-title":"Front Immunol"},{"key":"1_CR149","doi-asserted-by":"publisher","first-page":"554","DOI":"10.2215\/CJN.04760512","volume":"8","author":"V Fremeaux-Bacchi","year":"2013","unstructured":"Fremeaux-Bacchi V et al (2013) Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 8:554\u2013562","journal-title":"Clin J Am Soc Nephrol"},{"key":"1_CR150","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.2215\/CJN.02210310","volume":"5","author":"M Noris","year":"2010","unstructured":"Noris M et al (2010) Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 5:1844\u20131859","journal-title":"Clin J Am Soc Nephrol"},{"key":"1_CR151","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.preteyeres.2017.09.001","volume":"62","author":"CB Toomey","year":"2018","unstructured":"Toomey CB, Johnson LV, Bowes Rickman C (2018) Complement factor H in AMD: bridging genetic associations and pathobiology. Prog Retin Eye Res 62:38\u201357","journal-title":"Prog Retin Eye Res"},{"key":"1_CR152","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1136\/jmg.2006.045328","volume":"44","author":"A Servais","year":"2007","unstructured":"Servais A et al (2007) Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet 44:193\u2013199","journal-title":"J Med Genet"},{"key":"1_CR153","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.molimm.2015.03.012","volume":"67","author":"PF Zipfel","year":"2015","unstructured":"Zipfel PF et al (2015) The role of complement in C3 glomerulopathy. Mol Immunol 67:21\u201330","journal-title":"Mol Immunol"},{"key":"1_CR154","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1111\/ajt.12077","volume":"13","author":"ML Quintrec","year":"2013","unstructured":"Quintrec ML et al (2013) Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant 13:663\u2013675","journal-title":"Am J Transplant"},{"key":"1_CR155","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.imbio.2012.07.021","volume":"217","author":"SR de Cordoba","year":"2012","unstructured":"de Cordoba SR, Tortajada A, Harris CL, Morgan BP (2012) Complement dysregulation and disease: from genes and proteins to diagnostics and drugs. Immunobiology 217:1034\u20131046","journal-title":"Immunobiology"},{"key":"1_CR156","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/humu.9408","volume":"27","author":"S Heinen","year":"2006","unstructured":"Heinen S et al (2006) De novo gene conversion in the RCA gene cluster (1q32) causes mutations in complement factor H associated with atypical hemolytic uremic syndrome. Hum Mutat 27:292\u2013293","journal-title":"Hum Mutat"},{"key":"1_CR157","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1182\/blood-2011-03-339903","volume":"119","author":"NJ Francis","year":"2012","unstructured":"Francis NJ et al (2012) A novel hybrid CFH\/CFHR3 gene generated by a microhomology-mediated deletion in familial atypical hemolytic uremic syndrome. Blood 119:591\u2013601","journal-title":"Blood"},{"key":"1_CR158","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1681\/ASN.2017050518","volume":"29","author":"EG de Jorge","year":"2018","unstructured":"de Jorge EG et al (2018) Factor H Competitor Generated by Gene Conversion Events Associates with Atypical Hemolytic Uremic Syndrome. J Am Soc Nephrol 29:240\u2013249","journal-title":"J Am Soc Nephrol"},{"key":"1_CR159","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.molimm.2016.07.007","volume":"77","author":"X Xiao","year":"2016","unstructured":"Xiao X et al (2016) Familial C3 glomerulonephritis caused by a novel CFHR5-CFHR2 fusion gene. Mol Immunol 77:89\u201396","journal-title":"Mol Immunol"},{"key":"1_CR160","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/S0140-6736(10)60670-8","volume":"376","author":"DP Gale","year":"2010","unstructured":"Gale DP et al (2010) Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet 376:794\u2013801","journal-title":"Lancet"},{"key":"1_CR161","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/ki.2011.291","volume":"81","author":"A Tortajada","year":"2012","unstructured":"Tortajada A et al (2012) Complement factor H variants I890 and L1007 while commonly associated with atypical hemolytic uremic syndrome are polymorphisms with no functional significance. Kidney Int 81:56\u201363","journal-title":"Kidney Int"},{"key":"1_CR162","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1681\/ASN.2013070796","volume":"25","author":"MC Marinozzi","year":"2014","unstructured":"Marinozzi MC et al (2014) Complement factor B mutations in atypical hemolytic uremic syndrome-disease-relevant or benign? J Am Soc Nephrol 25:2053\u20132065","journal-title":"J Am Soc Nephrol"},{"key":"1_CR163","doi-asserted-by":"publisher","first-page":"4182","DOI":"10.1182\/blood-2011-10-383281","volume":"119","author":"LT Roumenina","year":"2012","unstructured":"Roumenina LT et al (2012) A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function. Blood 119:4182\u20134191","journal-title":"Blood"}],"container-title":["Methods in Molecular Biology","The Complement System"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-1016-9_1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T06:29:45Z","timestamp":1675146585000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-1016-9_1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9781071610152","9781071610169"],"references-count":163,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-1016-9_1","relation":{"is-part-of":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1007\/978-1-0716-1016-9","asserted-by":"object"}]},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"14 April 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}